SCHEMBL3370266

SCHEMBL3370266

Cn1c(C(Cl)(Cl)Cl)nc2cc(C(=O)O)ccc21

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 6/20 0.50
HSD17B10 Q99714 1/20 0.48
HTT P42858 1/20 0.47
PTGER4 P35408 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
HPGD P15428 2/20 0.44
ACSS2 Q9NR19 1/20 0.44
HCAR2 Q8TDS4 1/20 0.43
FGFR1 P11362 1/20 0.43
KDM4E B2RXH2 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
RXRA P19793 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2362098 0.85 KDM4E (0.55) HTTPTGER4NPC1RAB9AL3MBTL1
SCHEMBL1144927 0.78 HCAR3 (0.55) HCAR3HSD17B10HTTPTGER4SMN1; SMN2
SCHEMBL554569 0.78 HSD17B10 (0.64) HCAR3HSD17B10HTTSMN1; SMN2NPC1
SCHEMBL22121309 0.77 HCAR3 (0.54) HCAR3HSD17B10HTTPTGER4SMN1; SMN2
SCHEMBL17315023 0.77 HDAC6 (0.51) HCAR3HSD17B10HTTPTGER4HPGD
SCHEMBL16166626 0.77 HCAR3 (0.50) HCAR3HSD17B10HTTPTGER4SMN1; SMN2
SCHEMBL9412502 0.76 KMT2A (0.44) PTGER4SMN1; SMN2NPC1RAB9ATDP1
SCHEMBL25315207 0.76 HDAC1 (0.67) HCAR3HSD17B10HTTPTGER4TDP1
SCHEMBL19034792 0.76 HCAR3 (0.53) HCAR3HSD17B10HTTPTGER4SMN1; SMN2
Hydrochloric Acid SCHEMBL20969064 0.75 HDAC6 (0.50) HCAR3HSD17B10HTTPTGER4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1636216-B1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS SANOFI AVENTIS DEUTSCHLAND (DE) 2010-07-21 EP disclosed
US-7741341-B2 Benzimidazole-derivatives as factor Xa inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-06-22 US disclosed
EP-1636216-A1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS Sanofi-Aventis Deutschland GmbH (DE) 2006-03-22 EP disclosed
US-20050009829-A1 Benzimidazole-derivatives as factor Xa inhibitors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-01-13 US disclosed
WO-2004101553-A1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2004-11-25 WO disclosed
EP-1479676-A1 Benzimidazole-derivatives as factor xa inhibitors Aventis Pharma Deutschland GmbH (DE) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009829-A1 Benzimidazole-derivatives as factor Xa inhibitors F12, F11, F5 HCAR3 3532/4885HSD17B10 3777/4885HTT 4238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.